The Lancet Diabetes & Endocrinology in conversation with

Niki Karavitaki on the risk of brain tumours after radiotherapy for pituitary adenoma

07.19.2022 - By The Lancet GroupPlay

Download our free app to listen on your phone

Download on the App StoreGet it on Google Play

Niki Karavitaki talks with The Lancet Diabetes & Endocrinology about the risk of a second brain tumour after radiotherapy for pituitary adenoma or craniopharyngioma.Read the full article:Risk of second brain tumour after radiotherapy for pituitary adenoma or craniopharyngiomaContinue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://you...

More episodes from The Lancet Diabetes & Endocrinology in conversation with